Suven to present 5 posters at AAIC-2026 including masupirdine data

Suven to present 5 posters at AAIC-2026 including masupirdine data. The company will showcase updates from its Phase-3 masupirdine and Phase-2 usmarapride clinical trials at AAIC-2026 in London. These presentations highlight progress in its dementia and Alzheimer’s pipeline. Positive data could boost investor sentiment and stock movement.
📊 STOCKS: SUVENLIFE | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma